BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9769126)

  • 1. Bcl-2 expression in male breast carcinoma.
    Pich A; Margaria E; Chiusa L
    Virchows Arch; 1998 Sep; 433(3):229-35. PubMed ID: 9769126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma.
    Pich A; Margaria E; Chiusa L; Ponti R; Geuna M
    Hum Pathol; 1996 Jul; 27(7):676-82. PubMed ID: 8698311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenes in male breast cancer.
    Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
    Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear morphometry in male breast carcinoma: association with cell proliferative activity, oncogene expression, DNA content and prognosis.
    Chiusa L; Margaria E; Pich A
    Int J Cancer; 2000 Nov; 89(6):494-9. PubMed ID: 11102893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
    Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
    Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.
    Pich A; Margaria E; Chiusa L; Candelaresi G; Dal Canton O
    Br J Cancer; 1999 Feb; 79(5-6):959-64. PubMed ID: 10070897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis in breast carcinoma.
    González-Cámpora R; Galera Ruiz MR; Vázquez Ramírez F; Ríos Martín JJ; Fernández Santos JM; Ramos Martos MM; Gómez Pascual A
    Pathol Res Pract; 2000; 196(3):167-74. PubMed ID: 10729921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of mitotic index and Bcl2 expression in male breast cancer.
    Lacle MM; van der Pol C; Witkamp A; van der Wall E; van Diest PJ
    PLoS One; 2013; 8(4):e60138. PubMed ID: 23573235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative activity is a significant prognostic factor in male breast carcinoma.
    Pich A; Margaria E; Chiusa L
    Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma.
    Wick MR; Sayadi H; Ritter JH; Hill DA; Reddy VB; Gattuso P
    Am J Clin Pathol; 1999 Jan; 111(1):59-69. PubMed ID: 9894455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
    Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
    Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of bcl-2 expression with clinicopathological features in breast cancer.
    Lee HD; Koo JY; Jung WH
    Yonsei Med J; 1997 Aug; 38(4):206-11. PubMed ID: 9339128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
    Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
    Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis.
    Cui Q; Kong D; Li Z; Ahiable P; Wang K; Wu K; Wu G
    Clin Breast Cancer; 2018 Oct; 18(5):e875-e882. PubMed ID: 29478945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.